Follow Legend Biotech to never miss an important update.
The company has named Ingrid Zhang to the top leadership role as it works to turn its cancer treatment, Carvykti, into a standard early-stage therapy. This is a critical time for the business as it tries to reach profitability by scaling up its complex manufacturing process for cell therapies.
A sudden change at the top can sometimes be a sign of internal friction, but it also brings a fresh perspective to the company's goal of expanding its market share. For long-term owners, the focus remains on whether the new leadership can successfully manage the partnership with Johnson & Johnson and meet the high demand for its treatments.
Source: GlobeNewsWire
Oppenheimer analysts have lowered their rating on the stock to Perform, moving away from their previous bullish stance. This change comes shortly after the company reported its latest quarterly results and shared that its main cancer drug has now reached 10,000 patients.
While the drug continues to grow, a downgrade from a major firm often suggests analysts see fewer reasons for the stock to rise in the near term or have new concerns about the path to profitability. The firm set a price target of $40, which is still well above where the stock trades today but lower than the average target of $57 held by other analysts.
Source: Oppenheimer
Legend Biotech earned about 9 cents per share last quarter, topping the 7 cents analysts expected. Revenue reached about 390 million dollars, also beating estimates. The growth is coming from Carvykti, a cell therapy for bone marrow cancer that has now treated over 10,000 patients. Cell therapy is a complex process where a patient's own immune cells are re-engineered in a lab to fight cancer.
To keep up with demand, the company expanded its Raritan facility, making it the largest of its kind in the U.S. Management still expects the business to become profitable in 2026. This is a major milestone for a biotech firm, as it shows the company can successfully manufacture and sell its treatment at a scale that covers its high research and building costs.
Ying Huang has stepped down as CEO and board member effective immediately. He will stay on as an advisor through August to help with the handoff. Alan Bash, who leads the company's business operations, has been named interim CEO.
A sudden leadership change at a biotech company in the middle of a major product rollout can be disruptive. The company is currently focused on scaling up manufacturing for Carvykti, its treatment for multiple myeloma, a type of blood cancer. While the drug's clinical success is well-established, the new leadership must prove it can manage the complex logistics of producing cell therapies at a much larger scale.
Source: GlobeNewsWire
UBS analysts downgraded the stock from a buy-equivalent rating to Neutral and set a price target of $28. This is a sharp drop from the average analyst target of $53.
While the company's main drug, Carvykti, continues to show strong results in treating cancer, a downgrade like this often suggests concerns about how quickly the company can grow or how much it will cost to build out its labs. For a company that is not yet profitable, these manufacturing and spending hurdles are just as important as the science itself.
Source: UBS
The team often sets a bar they can clear, but recent results have turned choppy. This makes it harder to trust their short-term forecasts as they push toward their first full year of profit.
| Expectation | |
|---|---|
| EPS | $0.02 |
| Revenue | $361M |
Follow Legend Biotech to get the latest and most important updates.
Follow LEGN